• Strategic Partnership: ReNerve and Berkeley Biologics join forces to develop and commercialize two new tissue-based product ranges
• Accelerated Timeline: First product launch targeted for Q3 2025, second before year-end
• Market Synergy: New products complementary to ReNerve's existing nerve repair portfolio, sold through existing distribution network

ReNerve Limited (ASX:RNV), a medical device company transforming peripheral nerve repair, has announced a strategic partnership with Berkeley Biologics LLC to develop and commercialize two new complementary tissue-based product ranges. This collaboration strengthens ReNerve's position in the surgical tissue market and broadens its offerings to existing customers in the peripheral nerve injury (PNI) repair space. The two companies will initially focus on two product ranges: one addressing the need for human dermal tissue and the other providing a range of amniotic tissue products. These innovative solutions address multiple surgical applications including trauma and wound care, breast reconstruction, foot and ankle procedures, extremity repairs, and orthopedic and plastic surgeries. The products enable surgeons to incorporate additional tissue grafts when treating nerve injuries, addressing both the damaged nerve and underlying trauma. ReNerve plans to launch the first new product line in Q3 2025, with the second reaching market before year-end. The products will be produced in the US at Berkeley Biologics' California facility, and the two companies have entered an initial 5-year supply agreement. This partnership is expected to be a natural extension of ReNerve's current sales activities, using the same sales network and targeting the same surgeon and hospital customers.

The strategic partnership enhances ReNerve's comprehensive suite of surgical solutions in peripheral nerve injury repairs and related surgeries, positioning the company as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market.